Chinese COVID–19 vaccine developer Clover Biopharmaceuticals said on Thursday it raised $240 million in net proceeds in an initial public offering (IPO) of shares in Hong Kong.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
